system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Comorbidity, Deoxycytidine, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Prognosis, Survival Analysis.
user
Is comorbidity , not age , prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy? Context: To evaluate the impact of age and comorbidity on clinical outcomes in advanced pancreatic cancer. Consecutive 237 patients with advanced pancreatic cancer were studied. Comorbidity was scored by Charlson comorbidity index (CCI). We compared the clinical outcomes by age or comorbidity. Sixty-nine patients were elderly (≥75 years), and CCI was 0 in 69 patients, 1 in 98, and ≥2 in 70. Gemcitabine-based chemotherapy was administered in 183 patients and was well tolerated in both elderly group and in those with comorbidities. In a multivariate analysis, CCI, not age, was prognostic in addition to PS, distant metastasis, chemotherapy and CA19-9: the hazard ratios of CCI 1 and ≥2 were 1.25 and 1.55, compared with CCI 0 (p=0.027).
assistant
Gemcitabine-based chemotherapy can be an effective treatment, without significant toxicity, in elderly patients. Comorbidity, not age, was prognostic in patients with advanced pancreatic cancer. Final Decision: yes